Skip to main content

Research Repository

Advanced Search

Results from the tranexamic acid for primary intracerebral haemorrhage-2 (TICH-2) trial

Sprigg, Nikola; Flaherty, Katie; Law, Zhe Kang; Appleton, Jason P.; Scutt, Polly; Krishnan, Kailash; Bath, Philip M.

Results from the tranexamic acid for primary intracerebral haemorrhage-2 (TICH-2) trial Thumbnail


Authors

NIKOLA SPRIGG nikola.sprigg@nottingham.ac.uk
Professor of Stroke Medicine

Katie Flaherty

Zhe Kang Law

Jason P. Appleton

Polly Scutt

Kailash Krishnan

PHILIP BATH philip.bath@nottingham.ac.uk
Stroke Association Professor of Stroke Medicine



Abstract

Background: Haematoma expansion leads to worse outcome in intracerebral haemorrhage (ICH). Tranexamic acid (TXA) is a promising haemostatic agent to prevent haematoma expansion and improve outcome after ICH.
Methods: TICH-2 is a multicentre prospective double blind randomised controlled trial, which recruited patients presenting within 8 hours of primary ICH to receive intravenous TXA or placebo. Primary outcome is modified Rankin Scale at day 90 and will be analysed using ordinal logistic regression, adjusted for minimisation criteria. Secondary outcomes will be analysed using adjusted binary logistic regression and multiple linear regression; these include haematoma expansion at 24 hours, day 7 National Institute of Health Stroke Scale (NIHSS), day 90 Barthel Index, quality of life, cognition and mood.
Results: A total of 2325 patients were recruited between 14th March 2013 and 30th September 2017, from 12 countries: United Kingdom (n= 1910), Italy, Georgia, Switzerland, Malaysia, Hungary, Poland, Ireland, Turkey, Sweden, Denmark and Spain. Randomisation characteristics included: age 68.9 (13.8) years; male 1301 (56.0%); time from onset to randomisation 3.6 hours [2.6, 5.0]; NIHSS 13 (7.5); Glasgow coma scale 13.4 (2.1); systolic blood pressure 172.6 (27.2) mmHg; intraventricular haemorrhage 745 (32.0%) and prior antiplatelet use 610 (26.2%).
Conclusion: TICH-2 is the largest trial of TXA in spontaneous ICH and recruited over its original target of 2000 patients. The results will be available in May 2018 and will inform whether TXA should be recommended for the treatment of acute spontaneous ICH.

Citation

Sprigg, N., Flaherty, K., Law, Z. K., Appleton, J. P., Scutt, P., Krishnan, K., & Bath, P. M. (2018). Results from the tranexamic acid for primary intracerebral haemorrhage-2 (TICH-2) trial.

Conference Name 4th European Stroke Organisation Conference ​(ESOC 2018)
End Date May 18, 2018
Acceptance Date Feb 25, 2018
Publication Date May 16, 2018
Deposit Date Apr 13, 2018
Publicly Available Date May 16, 2018
Peer Reviewed Peer Reviewed
Public URL https://nottingham-repository.worktribe.com/output/932557

Files





You might also like



Downloadable Citations